Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07300462
Enrolling by invitation Phase 4

A Post-marketing Observational Study of Oral Cholera Vaccine

NCT07300462 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai United Cell Biotechnology Co., Ltd
Phase
Phase 4
Started
2026-04-10
Last updated
2026-07-10

Condition(s) studied

Diarrhea

Investigational drug(s) / intervention(s)

Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)Placebo

Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules): The participants in the experimental group will be given three oral doses of recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules) on D0, D7, and D28 .

Placebo: The participants in the Control group will be given three oral doses of recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules) Placebo on D0, D7, and D28 .

Study summary

Chinese survey data indicate that the incidence rate of diarrhea in the general population ranges from 0.17 to 0.70 episodes per person-year, whereas among children under five years of age, the rate is significantly higher, ranging from 2.50 to 3.38 episodes per person-year. Over recent decades, rapid economic development has contributed substantially to the reduction of mortality associated with infectious diseases. However, emerging challenges-such as increasing antimicrobial resistance and heightened population mobility-have complicated efforts in infectious disease prevention and control. In a phase III clinical trial of the recombinant B subunit/bacterial whole-cell cholera vaccine (enteric-coated capsule), a statistically significant difference was observed in the overall incidence of diarrhea between the vaccinated group (12.9%) and the control group (26.7%) (P \< 0.01). Findings from similar vaccine studies conducted in Sweden have demonstrated cross-protection against diarrhea caused by enterotoxigenic Escherichia coli (ETEC) and other intestinal pathogens. Specifically, the vaccine conferred a 50% protection rate against Salmonella enterica infections, 82% against mixed infections involving ETEC and Salmonella, and 71% against mixed infections involving ETEC and other pathogens. Evidence from relevant studies suggests that the recombinant B subunit/bacterial whole-cell cholera vaccine may offer protective benefits against non-cholera infectious diarrhea. Nevertheless, there remains a paucity of real-world effectiveness data, particularly in pediatric populations who bear a disproportionately high burden of diarrheal disease.

Eligibility

Sex
ALL
Min age
2 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age ≥ 2 years old, ≤ 14 years old, male or female. 2. Not vaccinated against cholera. 3. Obtain the consent of the study subject or guardian and sign the informed consent form. 4. The subjects and their guardians were able to comply with the requirements of the clinical study protocol. 5. Axillary temperature \< 37.0 °C was measured on the day of inoculation. Exclusion Criteria: * Exclusion Criteria for First Inoculation： 1. Patients with febrile illness (axillary temperature ≥ 37.0 °C on the day of vaccination), other acute diseases, and diarrhea within 7 days before vaccination. 2. Use of antibiotics within 7 days prior to vaccination. 3. Patients with gastric ulcer, abnormal gastric acid secretion and other gastric diseases or discomfort. 4. History of allergy to vaccinations and oral medications. 5. Patients with congenital malformations, developmental disorders, or severe chronic diseases. 6. Suspected progressive neurological disorder, epilepsy, or long-term use of antibiotics. 7. Received blood products within 3 months prior to vaccination. 8. Received other investigational drugs within 30 days prior to vaccination. 9. Received any Rotavirus vaccine within 12 months prior to vaccination. 10. Live attenuated vaccine within 14 days or subunit or inactivated vaccine within 7 days prior to vaccination. 11. Asthma requiring urgent treatment, hospitalization, intubation, oral or intravenous corticosteroids for unstable past two years. 12. Patients with severe hypertension, heart, liver, kidney disease, and severe infectious diseases (acquired immunodeficiency syndrome and active tuberculosis). 13. Has a malignancy, is active or has been treated without definitive cure, or has the potential to relapse during the study. 14. Epilepsy, excluding epilepsy that has been discontinued within the past 3 years and has not recurred. 15. Patients with coagulation disorders. 16. Those who have had or are currently suffering from mental illness that have not been well controlled within the past two years due to psychological conditions that do not comply with protocol requirements, and who need to take drugs for psychosis. 17. In the judgment of the investigator, it is contrary to the protocol due to various medical, psychological, social or other conditions, or affects the subject to sign the informed consent. * Exclusion Criteria for Second and Third Oral Vaccines： 1. Those who have an allergic reaction at the time of the first or second vaccination. 2. Occurring in any of the first dose exclusion criteria after inclusion. 3. Serious adverse event causally related to first or second dose of study vaccine.

Primary outcome measure(s)

  • the incidence of infectious diarrhea in the vaccinated group and placebo group — The incidence of diarrhea in the experimental group and the control group within 180 days starting from 7 days after full immunization (the baseline day for diarrhea)
    Protective effect of recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules) against infectious diarrhea due to enteropathogens (except Vibrio cholerae) (Day 7 after full immunization to the end of the study).

Trial sites (5)

FacilityCityRegionStatus
Anhui Provincial Center for Disease Control and Prevention Hefei Anhui
National Institute for Communicable Disease Control and Prevention, China Beijing Beijing Municipality
Hubei Provincial Center for Disease Control and Prevention Wuhan Hubei
Jiangsu Provincial Center for Disease Control and Prevention Nanjing Jiangsu
Shandong Provincial Center for Disease Control and Prevention Jinan Shandong

Other trials for the same condition

Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy Starting soon
Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients Starting soon
CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults Starting soon
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) Recruiting
Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07300462 on ClinicalTrials.gov ↗ ← All trials in China